Alba Hernández-García

Universidad de Murcia

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

M. Dolores Santana

Universidad de Murcia

Delia Bautista

Universidad de Murcia

José Ruiz

Universidad de Murcia

Enrique Ortega

Universidad de Murcia

Francisco J. Ballester

Universidad de Murcia

Lenka Marková

Czech Academy of Sciences, Institute of Biophysics

Viktor Brabec

Czech Academy of Sciences, Institute of Biophysics

Jana Kašpárková

Czech Academy of Sciences, Institute of Biophysics

Hana Kostrhunová

Czech Academy of Sciences, Institute of Biophysics

M. Alejandra Guerrero‐Rubio

Universidad de Murcia

Cooperative Institutions

Universidad de Murcia

Universitat de Barcelona

Hospital Universitario Miguel Servet

Czech Academy of Sciences, Institute of Biophysics

Czech Academy of Sciences

Palacký University Olomouc

Institut de Biomedicina de la Universitat de Barcelona

University of Edinburgh

Hospital Clínico Universitario Lozano Blesa

In-Q-Tel

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

A near-infrared light-activatable Ru(ii)-coumarin photosensitizer active under hypoxic conditions

Chemical Science (2023)

Enrique Ortega Anna Rovira Marta López‐Corrales Alba Hernández-García Francisco J. Ballester

Photodynamic therapy (PDT) represents a promising approach for cancer treatment. However, the oxygen dependency of PDT to generate reactive oxygen species (ROS) hampers its therapeutic efficacy, especially against hypoxic solid tumors. In addition, some photosensitizers (PSs) have dark toxicity and are only activatable with short wavelengths such as blue or UV-light, which suffer from poor tissue penetration. Herein, we developed a novel hypoxia-active PS with operability in the near-infrared (NIR) region based on the conjugation of a cyclometalated Ru(ii) polypyridyl complex of the type [Ru(C^N)(N^N)2] to a NIR-emitting COUPY dye. The novel Ru(ii)-coumarin conjugate exhibits water-solubility, dark stability in biological media and high photostability along with advantageous luminescent properties that facilitate both bioimaging and phototherapy. Spectroscopic and photobiological studies revealed that this conjugate efficiently generates singlet oxygen and superoxide radical anions, thereby achieving high photoactivity toward cancer cells upon highly-penetrating 740 nm light irradiation even under hypoxic environments (2% O2). The induction of ROS-mediated cancer cell death upon low-energy wavelength irradiation along with the low dark toxicity exerted by this Ru(ii)-coumarin conjugate could circumvent tissue penetration issues while alleviating the hypoxia limitation of PDT. As such, this strategy could pave the way to the development of novel NIR- and hypoxia-active Ru(ii)-based theragnostic PSs fuelled by the conjugation of tunable, low molecular-weight COUPY fluorophores.

Conjugate

Tumor Hypoxia

10.1039/d3sc01844j

Cite

Citations (31)

Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab.

Dermatology Online Journal (2019)

Tamara Gracia‐Cazaña Esteban Padgett Alba Hernández-García María Pilar Sánchez-Salas

Anti-programmed cell death (PD)-1 therapies in metastatic tumors have a high incidence of immune adverse events, including cutaneous manifestations such as vitiligo-like lesions. This side effect is associated with increased survival and it is a clinical marker of response to treatment. This case report is a graphic representation of the appearance of vitiligo-like lesions over in-transit metastases of malignant melanoma linked to a complete response to treatment with pembrolizumab.

Vitiligo

10.5070/d32512046728

Cite

Citations (2)

CCDC 1968967: Experimental Crystal Structure Determination

The Cambridge Structural Database (2020)

Enrique Ortega Francisco J. Ballester Alba Hernández-García Samanta Hernández‐García M. Alejandra Guerrero‐Rubio

10.5517/ccdc.csd.cc242w26

Cite

Citations (0)

New cyclometalated Ru(ii) polypyridyl photosensitizers trigger oncosis in cancer cells by inducing damage to cellular membranes

Inorganic Chemistry Frontiers (2024)

Jakub Červinka Alba Hernández-García Delia Bautista Lenka Marková Hana Kostrhunová

A new generation of benzimidazole-based cyclometalated ruthenium( ii ) complexes with bpy or dpq as ancillary ligands are effective against hypoxic cancers via green light activation and can directly disrupt phospholipid membranes and trigger oncosis.

10.1039/d4qi00732h

Cite

Citations (4)

CCDC 2226215: Experimental Crystal Structure Determination

The Cambridge Structural Database (2023)

Alba Hernández-García Lenka Marková M. Dolores Santana Jitka Prachařová Delia Bautista

An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.

10.5517/ccdc.csd.cc2dqkd3

Cite

Citations (0)

Novel 2-(5-Arylthiophen-2-yl)-benzoazole Cyclometalated Iridium(III) dppz Complexes Exhibit Selective Phototoxicity in Cancer Cells by Lysosomal Damage and Oncosis

Journal of Medicinal Chemistry (2023)

Jana Kašpárková Alba Hernández-García Hana Kostrhunová Marta Goicuría Vojtěch Novohradský

A second-generation series of biscyclometalated 2-(5-aryl-thienyl)-benzimidazole and -benzothiazole Ir(III) dppz complexes [Ir(C^N)2(dppz)]+, Ir1–Ir4, were rationally designed and synthesized, where the aryl group attached to the thienyl ring was p-CF3C6H4 or p-Me2NC6H4. These new Ir(III) complexes were assessed as photosensitizers to explore the structure–activity correlations for their potential use in biocompatible anticancer photodynamic therapy. When irradiated with blue light, the complexes exhibited high selective potency across several cancer cell lines predisposed to photodynamic therapy; the benzothiazole derivatives (Ir1 and Ir2) were the best performers, Ir2 being also activatable with green or red light. Notably, when irradiated, the complexes induced leakage of lysosomal content into the cytoplasm of HeLa cancer cells and induced oncosis-like cell death. The capability of the new Ir complexes to photoinduce cell death in 3D HeLa spheroids has also been demonstrated. The investigated Ir complexes can also catalytically photo-oxidate NADH and photogenerate 1O2 and/or •OH in cell-free media.

Phototoxicity

Benzothiazole

HeLa

Benzimidazole

10.1021/acs.jmedchem.3c01978

Cite

Citations (17)

Cyclometalated Benzimidazole Osmium(II) Complexes Inhibit the Proliferation of Cancer Cells and Disrupt Calcium Homeostasis

SSRN Electronic Journal (2022)

Alba Hernández-García Lenka Marková M. Dolores Santana Jitka Prachařová Viktor Brabec

We present the synthesis and characterization of six new heteroleptic osmium(II) complexes of the type [Os(C^N)(N^N) 2 ]OTf (N^N = 2,2′-bipyridine, dipyrido[3,2-d:2',3'-f]quinoxaline; C^N = deprotonated methyl 1-butyl-2aryl-benzimidazolecarboxylate) with varying substituents in the R3 position of the phenyl ring of the cyclometalating C^N ligand. The new compounds are highly kinetically inert and absorb a full-wavelength range of visible light. An investigation of the antiproliferative activity of the new compounds has been performed using a panel of human cancer and noncancerous 2D cell monolayer cultures under dark conditions and green light irradiation. The results demonstrate that the new Os(II) complexes are markedly more potent than conventional cisplatin and that their activity is promoted by irradiation by green light. Promising antiproliferative activity of selected Os(II) complexes was also confirmed using 3D multicellular tumor spheroids, which have the characteristics of solid tumors and can mimic the tumor tissue microenvironment. The mechanism of antiproliferative action of complexes has also been investigated and revealed that under dark conditions, the investigated Os(II) complexes activate the endoplasmic reticulum stress pathway in cancer cells and disrupt calcium homeostasis.

Benzimidazole

Homeostasis

Osmium

10.2139/ssrn.4221729

Cite

Citations (0)

CCDC 1968966: Experimental Crystal Structure Determination

The Cambridge Structural Database (2020)

Enrique Ortega Francisco J. Ballester Alba Hernández-García Samanta Hernández‐García M. Alejandra Guerrero‐Rubio

10.5517/ccdc.csd.cc242w15

Cite

Citations (0)

Metastatic extraskeletal Ewing's sarcoma treated with trabectedin: A case report

Oncology Letters (2016)

Jorge Hernando-Cubero Pilar M. Sanz-Moncasi Alba Hernández-García Isabel Pajares-Bernard Javier Martínez‐Trufero

The Ewing's sarcoma family of tumors (ESFT) comprises a number of rare malignant tumors. Standard first-line treatment for patients with these tumors includes chemotherapy with a five-drug regimen of vincristine, doxorubicin (Adriamycin®) and cyclophosphamide, alternating with ifosfamide and etoposide (VAC/IE). In cases of inadequate response, there are a number of second-line regimens available. However, further treatment options are required for those patients with disease unresponsive to standard treatment. Trabectedin is a novel treatment option for patients with ESFT. The present study reports the case of a Caucasian 69-year-old female patient who presented with a soft tissue mass on the chest wall that had developed 7 months earlier. A computed tomography scan revealed a 9×8×7-cm mass on the anterior chest wall above the pectoral muscle. Histopathological evaluations and molecular analysis indicated that it was consistent with a metastatic extraskeletal Ewing's sarcoma. The patient was treated with an alternating VAC/IE regimen; however, an inadequate response was observed. The patient received second-line treatment with a gemcitabine and dacarbazine combination regimen, but the disease progressed. Subsequently, treatment with trabectedin (1.5 mg/m2 as a 24-h continuous infusion every 3 weeks) was initiated. Trabectedin treatment resulted in long-lasting (18 months) progression-free survival. It is vital that novel drugs continue to being developed for patients with ESFT following progression subsequent to standard chemotherapy. The current report presents a case of a patient with metastatic, pre-treated Ewing's sarcoma achieving disease stabilization with trabectedin. Based on these results and the observed tolerability profile, trabectedin represents an alternative treatment for patients with ESFT. Further studies are required in order to determine the efficacy of trabectedin as monotherapy or in combination with other drugs. It is also important to identify which tumor subtypes, specific translocations and patient profiles will benefit the most from treatment with trabectedin.

Trabectedin

Regimen

Dacarbazine

10.3892/ol.2016.4950

Cite

Citations (7)

A novel benzothiazole-1,2,3-triazole-based arene osmium(II) complex as an effective rhabdomyosarcoma cancer stem cell agent

Inorganic Chemistry Frontiers (2025)

Sofia Sharkawy Alba Hernández-García Hana Kostrhunová Delia Bautista Lenka Marková

We designed a series of pseudo-octahedral arene Os(II) complexes ( Os1 – Os5 ) with the general formula [(η 6 - p -cym)Os(BTAT)Cl] + , where BTAT represents chelating N^N′ ligands based on the 1-aryl-4-benzothiazolyl-1,2,3-triazole scaffold. The structures of Os3 ...

Benzothiazole

Osmium

Triazole

10.1039/d4qi02737j

Cite

Citations (0)